An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Recent work has discovered the role of the cyclin-dependent kinase (CDK)-binding protein ... DNA replication and is aberrantly enhanced in cancer. Surprisingly, new work indicates that this ...

Explore the future of cancer treatment with AI-powered drug discovery, featuring novel CDK12/13 dual inhibitors.

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

HER2-negative advanced-stage breast cancer receiving deferred (second-line) versus first-line cyclin dependent-kinase (CDK) 4/6 inhibitors have noninferior progression-free survival after second ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in ...

Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...

(Alliance News) - AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

Get Instant Summarized Text (Gist) Cyclin-dependent kinase 2 (CDK2) is identified as a potential target for cancer therapy, particularly in overcoming resistance to CDK4/6 inhibitors used in ...

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...